Fulltext

Nanomaterials in Alzheimer's disease treatment: a comprehensive review

Faiyaz M 1 , Ganayee MA 2 , Akhtar S 1 , Krishnan S 3 , Flora B 4 , Dogra D 5 Show all authors , Jha NK 6 , Chellappan DK 7 , Negi P 8 , Dua K 9 , Kesari KK 10 , Gupta PK 11

Affiliations 

  • 1 Department of Bioengineering, Integral University, Kursi Road, 226026 Lucknow, Uttar Pradesh, India
  • 2 Department of Chemistry, Indian Institute of Technology Madras, 600036 Chennai, Tamil Nadu, India
  • 3 Dhanvantari Nano Ayushadi Pvt Ltd, 600017 Chennai, Tamil Nadu, India
  • 4 Department of Biotechnology, School of Biosciences & Bioengineering, Lovely Professional University, 144411 Phagwara, Punjab, India
  • 5 School of Biological and Environment Sciences, Shoolini University, 173229 Solan, Himachal Pradesh, India
  • 6 Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, 201310 Greater Noida, Uttar Pradesh, India
  • 7 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), 57000 Bukit Jalil, Kuala Lumpur, Malaysia
  • 8 School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, 173212 Solan, Himachal Pradesh, India
  • 9 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, 2007 NSW, Australia
  • 10 Department of Applied Physics, School of Science, Aalto University, 00076 Espoo, Finland
  • 11 Department of Life Sciences, School of Basic Sciences and Research (SBSR), Sharda University, Knowledge Park III, 201310 Greater Noida, Uttar Pradesh, India
Front Biosci (Landmark Ed), 2021 10 30;26(10):851-865.
PMID: 34719210 DOI: 10.52586/4992

Abstract

Alzheimer's, a progressive neurodegenerative disease affects brain and neurons through enormous reduction in nerve cell regenerative capacity. Dementia and impairment of cognitive functions are more prevalent in Alzheimer's disease (AD) patients in both industrialized and non-industrialized countries. Various factors play significant role in molecular cascades that leads to neuronal inflammation, dementia and thereby AD progression. Current medications are symptomatic that alleviates pain while lack in absolute cure, urging researchers to explore targets and therapeutics. Interestingly, nanomedicines developed due to the onset of nanotechnology, are being extensively investigated for the treatment of AD. This review presents the advancement in nanotherapeutic strategies, involving the emergence of nanomaterials that offers advantage to pass through the blood-brain barrier and acts as a therapeutic modality against AD.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications